Latest investigations into retatritide peptide reveal promising potential for managing weight and non-insulin dependent disease. The peptide, a dual stimulator of GLP-1 and GIP receptor, looks to present improved weight loss and glucose control versus existing treatments. Further clinical trials are required to fully assess its safety profile and l